Comparison of seroconversion rates between low-dose intradermal and recommended dose intramuscular hepatitis B vaccination in children
Abstract
Introduction Massive hepatitis B vaccination is expensive. Re-sults of studies showed that reduced dosage given intradermally
to adults and intramuscularly to children were able to induce
seroconversion.
Objective To compare the anti-HBs seroconversion (seropositive
and seroprotective) rates between intradermal low-dose of 2 mg
(ID-2) and intramuscular recommended dose of 10 mg (IM-10)
vaccination against hepatitis B.
Methods In a randomized clinical trial, using the hepatitis B plasma
vaccine, elementary school children in Tanjung Enim subdistrict,
80-168 months of age, were randomly assigned to be given three
doses of either the ID-2 (n=59) or IM-10 (n=64) vaccinations at
one month intervals. Seropositive (anti HBs titer >2.1 mIU/l) and
seroprotective (anti HBs >10 mIU/l) rates as well as the seroposi-
tive and seroprotective geometric mean antibody titers (GMTs) were
compared one month after each inoculation. A p value of <0.1
was considered statistically significant.
Results One month after the third inoculation, there was no sig-
nificant difference in the seropositive rate (95% vs. 89%),
seroprotective rate (85% vs. 83%), seropositive GMTs (55.85 mIU/
l vs. 61.24mIU/l), and seroprotective GMTs (73.86 mIU/l vs. 72.49
mIU/l) between the ID-2 and the IM-10 groups (all with p>0.1)
Conclusion Reduced doses of the hepatitis B vaccine given in-
tradermally may offer protection against hepatitis B, thus it may be
useful for mass vaccination programs
References
dan pencegahan hepatitis B. 1 st ed. Jakarta: Yayasan
Penerbitan Ikatan Dokter Indonesia; 1998.
2. Hidayat B. Pemberian vaksin hepatitis B pada anak secara
universal. Proceedings of the Symposium on up date of
hepatitis B prevention in children; 1993 Aug; p.1-6.
3. Sulaiman A, Julitasari. Virus hepatitis A sampai E di
Indonesia. Jakarta: Yayasan Penerbit Ikatan Dokter
Indonesia; 1995.p.16-76.
4. Direktorat Jenderal PPM dan PLP Depkes RI. 2 nd ed.
Petunjuk teknis pelaksanaan imunisasi hepatitis B.
Jakarta: Departemen Kesehatan; 1996. p.1-20.
5. Redfield RR, Innis BL, Scott RM, Cannon HG,
Bancroft WH. Clinical evaluation of low-dose intrad-
ermally administered hepatitis B virus vaccine: a cost-
reduction strategy. JAMA 1985;254:3203-6.
6. Bryan JP, Sjogren MH, Perine PL, Legters LJ. Review
articles: low dose intramuscular vaccination against
hepatitis B. Clin Infect Dis 1992; 14: 697-707.
7. Wahl M, Hermodsson S. Intradermal, subcutaneous
or intramuscular administration of hepatitis B vaccine:
side effects, antibody response. Scand J Infect Dis
1987;19:617-21
8. Miller KD, Mulligan MW, Gibbs RD, Hutman TS, Francis
DP. Intradermal HBV vaccination: immunogenicity and
side effects in adults. Lancet 1983;2:1454-56.
9. Bryan JP, Sjogren M, Igbal M, Khattak AR, Nabi S,
Ahmed A, et al. Comparative trial of low-dose, intrad-
ermal recombinant and plasma derived hepatitis B vac-
cines. J Inf Dis 1990;162:789-793.
10. Leonardi S, Musumeci S, Sciacca A, Greco D, Romano
C. Reliability of intradermal vaccination against hepa-
titis B for accelerated prophyalxis. Pediatr Infect Dis
1990;336:520.
11. Thomson SC, Darlington R, Tallent DB, Forsyth JRL.
Effectiveness of low dose intradermal hepatitis B vac-
cination: five years’ experience of primary vaccination.
Med J Austr 1993;158:372-8.
12. Coleman PJ, Shaw FE, Hadler SC, Margolis HS,
Serovich J. Intradermal hepatitis B vaccination in a large
hospital employee population. Vaccine 1991;7:58-62.
13. Clark JA, Hollinger FB, Lewis E, Russell LA, Miller
CH, Huntley AC, et al. Intradermal inoculation with
Heptavax B: immune response and histologic evalua-
tion of injection sites. JAMA 1989;262:2567-71.
14. NN. Low-dose vaccine in children: impressive perfor-
mance holds promise of cost savings. Hevac Bulletin
1995;3:1-3
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Accepted 2016-09-23
Published 2016-09-24